Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2007;49:1409-1414
Published online before print May 7, 2007, doi: 10.1161/HYPERTENSIONAHA.106.080994
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
49/6/1409    most recent
HYPERTENSIONAHA.106.080994v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Iekushi, K.
Right arrow Articles by Morishita, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Iekushi, K.
Right arrow Articles by Morishita, R.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Heart Attack
Related Collections
Right arrow Structure
Right arrow Acute myocardial infarction
Right arrow Congestive
Right arrow Myocardial cardiomyopathy disease
Right arrow ACE/Angiotension receptors
Right arrow Animal models of human disease

(Hypertension. 2007;49:1409.)
© 2007 American Heart Association, Inc.


Original Articles

Novel Mechanisms of Valsartan on the Treatment of Acute Myocardial Infarction Through Inhibition of the Antiadhesion Molecule Periostin

Kazuma Iekushi; Yoshiaki Taniyama; Junya Azuma; Naruto Katsuragi; Norio Dosaka; Fumihiro Sanada; Nobutaka Koibuchi; Kaori Nagao; Toshio Ogihara; Ryuichi Morishita

From the Departments of Clinical Gene Therapy (K.I., Y.T., J.A., N.K., N.D., F.S., N.K., K.N., R.M.) and Geriatric Medicine (K.I., Y.T., J.A., N.K., N.D., T.O., R.M.), Graduate School of Medicine, Osaka University, Suita, Japan.

Correspondence to Ryuichi Morishita, Department of Clinical Gene Therapy, Osaka University Graduate School of Medicine, Suita 565-0871, Japan. E-mail morishit{at}cgt.med.osaka-u.ac.jp

Our previous study demonstrated that periostin, an extracellular matrix protein, plays an important role in left ventricular remodeling through the inhibition of cell–cell interactions. Because the gene regulation of periostin has not yet been examined, we focused on the effects of angiotensin (Ang) II and mechanical stretch, because Ang II and mechanical stretch are related to cardiac remodeling after myocardial infarction. First, we examined the effects of Ang II on periostin in myocytes and fibroblasts in vitro. Ang II significantly increased periostin through phosphatidylinositol 3-kinase, c-Jun N-terminal kinase, p38, and extracellular signal-regulated kinase 1/2 pathways in myocytes and fibroblasts (P<0.05). On the other hand, mechanical stretch also significantly increased periostin expression (P<0.05). This increase was inhibited partially, but significantly, by an Ang II receptor blocker, valsartan, and inhibited almost completely by valsartan with the neutralization antibodies for transforming growth factor-ß and platelet-derived growth factor–BB (P<0.05). Therefore, we further examined periostin expression in vivo. Periostin expression was significantly increased in infarcted myocardium (P<0.05), and treatment with valsartan significantly attenuated it at 4 weeks after myocardial infarction (P<0.05), accompanied by a significant improvement in cardiac dysfunction (P<0.05). Overall, the present study demonstrated that Ang II, as well as mechanical stretch, stimulated periostin expression in both cardiac myocytes and fibroblasts, whereas valsartan significantly attenuated the increase in periostin expression. The inhibition of periostin by valsartan might especially contribute to its beneficial effects on cardiac remodeling after myocardial infarction.


Key Words: angiotensin II type 1 receptor blockers • myocardial infarction • adhesions • fibrosis • ventricular remodeling




This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
T. Urashima, M. Zhao, R. Wagner, G. Fajardo, S. Farahani, T. Quertermous, and D. Bernstein
Molecular and physiological characterization of RV remodeling in a murine model of pulmonary stenosis
Am J Physiol Heart Circ Physiol, September 1, 2008; 295(3): H1351 - H1368.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
P. Snider, R. B. Hinton, R. A. Moreno-Rodriguez, J. Wang, R. Rogers, A. Lindsley, F. Li, D. A. Ingram, D. Menick, L. Field, et al.
Periostin Is Required for Maturation and Extracellular Matrix Stabilization of Noncardiomyocyte Lineages of the Heart
Circ. Res., April 11, 2008; 102(7): 752 - 760.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
D. P. Kolditz, M. C.E.F. Wijffels, N. A. Blom, A. van der Laarse, N. D. Hahurij, H. Lie-Venema, R. R. Markwald, R. E. Poelmann, M. J. Schalij, and A. C. Gittenberger-de Groot
Epicardium-Derived Cells in Development of Annulus Fibrosis and Persistence of Accessory Pathways
Circulation, March 25, 2008; 117(12): 1508 - 1517.
[Abstract] [Full Text] [PDF]


Home page
J. Exp. Med.Home page
M. Shimazaki, K. Nakamura, I. Kii, T. Kashima, N. Amizuka, M. Li, M. Saito, K. Fukuda, T. Nishiyama, S. Kitajima, et al.
Periostin is essential for cardiac healingafter acute myocardial infarction
J. Exp. Med., February 18, 2008; 205(2): 295 - 303.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
T. K. Borg and R. Markwald
Periostin: More Than Just an Adhesion Molecule
Circ. Res., August 3, 2007; 101(3): 230 - 231.
[Full Text] [PDF]